Vale P R, Isner J M, Rosenfield K
Department of Vascular Medicine, St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA.
J Interv Cardiol. 2001 Oct;14(5):511-28. doi: 10.1111/j.1540-8183.2001.tb00367.x.
Research in animal models of ischemia has shown that administration of angiogenic growth factors, either as a recombinant protein or by gene transfer, can augment nutrient perfusion through neovascularization to promote the development of supplemental collateral blood vessels that will constitute endogenous bypass conduits around occluded native arteries; a strategy termed "therapeutic angiogenesis." In animal models and clinical trials, the best studied cytokines with angiogenic activity are vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF). Clinical trials of therapeutic angiogenesis in patients with critical limb ischemia demonstrated resolution of rest pain and/or improved limb integrity, increased pain-free walking time and ankle-brachial index, newly visible collateral vessels by digital subtraction angiography, and qualitative evidence of improved distal flow by magnetic resonance imaging. Initial clinical trials in patients with end-stage coronary artery disease using direct myocardial injection via thoracotomy resulted in large increases in exercise time and marked reductions in anginal symptoms, as well as objective evidence of improved perfusion and left ventricular function. Larger scale placebo-controlled trials have been limited to intracoronary and intravenous administration of recombinant protein, and have not shown significant improvement in exercise time or angina compared to placebo. Larger scale placebo-controlled studies of gene transfer using catheter-based endocardial delivery are in progress. Future clinical studies are required to determine the optimal dose, formulation, route of administration, and combinations of growth factors, as well as the requirement for endothelial progenitor cell or stem cell supplementation, to provide effective and safe therapeutic angiogenesis for patients with critical limb ischemia and chronic myocardial ischemia who are not candidates for conventional revascularization procedures.
对缺血动物模型的研究表明,给予血管生成生长因子,无论是作为重组蛋白还是通过基因转移,都可以通过新血管形成增加营养物质灌注,以促进补充性侧支血管的发育,这些血管将构成阻塞的天然动脉周围的内源性旁路管道;这一策略被称为“治疗性血管生成”。在动物模型和临床试验中,研究最多的具有血管生成活性的细胞因子是血管内皮生长因子(VEGF)和成纤维细胞生长因子(FGF)。对严重肢体缺血患者进行治疗性血管生成的临床试验表明,静息痛得到缓解和/或肢体完整性得到改善,无痛行走时间和踝臂指数增加,数字减影血管造影显示有新的可见侧支血管,磁共振成像有远端血流改善的定性证据。在终末期冠状动脉疾病患者中,通过开胸直接心肌注射进行的初步临床试验使运动时间大幅增加,心绞痛症状明显减轻,同时有灌注改善和左心室功能改善的客观证据。更大规模的安慰剂对照试验仅限于冠状动脉内和静脉内给予重组蛋白,与安慰剂相比,运动时间或心绞痛方面未显示出显著改善。使用基于导管的心内膜递送进行基因转移的更大规模安慰剂对照研究正在进行中。未来需要进行临床研究,以确定最佳剂量、制剂、给药途径以及生长因子的组合,以及内皮祖细胞或干细胞补充的需求,为不适合进行传统血管重建手术的严重肢体缺血和慢性心肌缺血患者提供有效且安全的治疗性血管生成。